Maria Symiakaki/ LinkedIn
May 29, 2026, 09:50
Maria Symiakaki: Advancing Cardiovascular Prevention at the 2026 Congress of the European Atherosclerosis Society
Maria Symiakaki, Co-Founder and Public Affairs Business Development Director at Solutions for Rare Diseases (SfRD), shared a post on LinkedIn:
“Happy to attend the 2026 Congress of the European Atherosclerosis Society.
It was an excellent opportunity for global leaders in lipidology and preventive cardiology to reconnect, exchange ideas, and explore the future of cardiovascular prevention and lipid management.
Key highlights included the release of the new EAS consensus on pediatric familial hypercholesterolemia (FH), as well as advances in global lipid clinic networks.
Importantly, patient voices continue to play a central role in shaping cardiovascular health policy and care pathways across Europe.”
Stay updated with Hemostasis Today.
-
May 29, 2026, 09:37Katie Baca-Motes: What Can Menstrual Cycle Physiology Tell Us About Health Beyond Reproduction?
-
May 29, 2026, 09:35Torben Boelk: Bringing Plasma Donation to the Heart of Leipzig
-
May 29, 2026, 04:37Josefin Ahnström: How Andexanet Alfa Impacts TFPIα Function
-
May 29, 2026, 03:19Building Safer Systems for Anticoagulation Management – ISTH
-
May 29, 2026, 03:07Early Diagnosis Can Change the Lives of Women With Haemophilia – EHC
-
May 29, 2026, 02:41Ifeanyichukwu Ifechidere: The Biggest DOAC Myth in Coagulation – ‘No Monitoring Required’
-
May 29, 2026, 02:35Mariam Swidan: Why Is LDH the ‘Tattletale’ of the Lab?
-
May 29, 2026, 02:20Yuntian Wang: Multi-View Learning for Predicting Avatrombopag Response in Pediatric Immune Thrombocytopenia
-
May 29, 2026, 01:57Giuseppina Caligiuri: Pathophysiological Challenges and Emerging Therapeutic Strategies in Acute Stroke